Exhibit 99.1 Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update AUSTIN, Texas, August 12, 2025 (GLOBE NEWSWIRE) — Aspira Women's Health Inc. ("Aspira") (OTCQB: AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress under its new lead ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738 (Address of principal executive offices) (Zip Code) For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: ...

Q2 2025 Net Revenue of $127.3 million and Adjusted EBITDA1 of $28.6 million Tenth straight quarter of positive operating cash flow with $17.8 million generated Frank Perullo, Co-Founder and President of AWH, added, "Q2 delivered strong progress, including the addition of three new stores in key markets and the debut of our new infused brand, High Wired. We also ramped up commercialization of higher-margin, top-selling SKUs, launching 225 in the first half of 2025. Our products continue to gain strong consum ...

Core Points - Ascend Wellness Holdings, Inc. will hold a conference call on August 7, 2025, at 5:00 PM ET to discuss its second quarter 2025 financial results [1] - The earnings conference call can be accessed via a dial-in number or a live webcast on the company's Investor Relations website [2][3] Company Overview - Ascend Wellness Holdings, Inc. is a vertically integrated cannabis operator with assets in multiple states including Illinois, Maryland, Massachusetts, Michigan, New Jersey, Ohio, and Pennsylvania [4] - The company operates state-of-the-art cultivation facilities and produces a variety of products under several brands, including Simply Herb, Ozone, Ozone Reserve, High Wired, Effin', Common Goods, and Royale [4]

Financial Performance - Total revenue for the three months ended March 31, 2025, was $2,279,000, representing an increase of 5.85% compared to $2,153,000 for the same period in 2024[12] - Gross profit for the same period was $1,560,000, up from $1,214,000, indicating a gross margin improvement[12] - The net loss for the three months ended March 31, 2025, was $1,853,000, a reduction from a net loss of $4,629,000 in the prior year, reflecting a 60% improvement[12] - Operating expenses of $4,800,000 for the three months ended March 31, 2025, down from $5,924,000 in the same period of 2024, a decrease of 18.9%[12] - The company reported a net loss of $1,853,000 for Q1 2025, a 60% improvement compared to a net loss of $4,629,000 in Q1 2024[177] Cash and Liquidity - Cash and cash equivalents increased to $3,312,000 as of March 31, 2025, compared to $1,769,000 at the end of 2024[10] - Total current liabilities decreased to $3,791,000 from $5,468,000, showing a reduction of approximately 30.7%[10] - The company plans to take further actions to protect its liquidity position, including potential capital raising efforts[23] - The Company expects cash from product sales and licensing to be its only material, recurring source of cash in 2025, raising substantial doubt about its ability to continue as a going concern within one year[25] Research and Development - Research and development expenses were $973,000, slightly up from $906,000, indicating continued investment in product development[12] - The company entered into a consulting agreement with Biodesix, Inc., incurring $116,000 in research and development expenses as of March 31, 2025[129] - The OVAinform test is being developed in collaboration with leading institutions, aiming to improve ovarian cancer risk assessment through a multi-marker approach[169] - The company is developing a new non-invasive test for endometriosis, with a confirmed algorithm from three independent cohorts[156] Equity and Financing - The Company raised approximately $3,484,000 from the sale of 12,277,441 shares under the 2024 At the Market Offering during Q1 2025[92] - The gross proceeds from the 2024 Direct Offering were approximately $5,563,000, with expenses of about $733,000 deducted[100] - A private placement was initiated on March 5, 2025, raising a gross principal amount of $1,365,500 through Senior Secured Convertible Promissory Notes[207] - The conversion of the Convertible Notes occurred on March 12, 2025, resulting in the issuance of 5,465,850 shares and warrants to purchase 12,298,177 shares[208] Market and Product Development - The addressable market for the company's tests has increased to between 2 and 4 million tests per year, following the successful expansion of the OvaWatch test features[154] - The OVAinform development program is progressing, with an expected addressable market increase to 2,800,000 by including patients with genetic and familial risk[155] - The company plans to broaden its commercial focus to include differential diagnosis of various gynecological diseases, expanding beyond ovarian cancer[150] - The endometriosis portfolio targets an addressable market of over 6.5 million women in the U.S., indicating significant demand for non-invasive diagnostics[157] Cost Management - The Company has implemented cost-reduction strategies, including reducing executive bonuses and discretionary marketing programs, to manage financial challenges[27] - Sales and marketing expenses decreased by 43% to $1,058,000 in Q1 2025 from $1,861,000 in Q1 2024, mainly due to lower personnel and travel costs[183] - General and administrative expenses decreased by 12% to $2,823,000 in Q1 2025 from $3,211,000 in Q1 2024, attributed to reduced personnel and legal fees[184] Stock and Warrants - The Company recorded fair value of the 2022 Warrants as approximately $1,000 as of March 31, 2025, down from $60,000 as of December 31, 2024, indicating significant volatility in warrant valuations[44] - The fair value of the March 2025 Warrants was approximately $616,000 as of March 31, 2025, down from $1,477,000 on the date of issuance, reflecting a change in fair value of $861,000 reported in the statement of operations[49] - The Company has outstanding warrants to purchase shares of its common stock, but there is no assurance that these warrants will be exercised[24] Compliance and Regulatory - The company’s common stock was delisted from Nasdaq due to failure to meet the minimum stockholders' equity requirement of $2.5 million, and is now traded on the OTC Markets Group[138] - The company has a non-refundable royalty payment obligation of up to $1,350,000 based on regulatory approvals and commercialization milestones under the Dana-Farber, Brigham, Lodz License Agreement[78]

Financial Performance - Revenue for Q1 2025 was approximately $2.28 million, a 5.9% increase from $2.15 million in Q1 2024, driven by select price increases[1] - Gross profit increased to approximately $1.6 million in Q1 2025, representing a 28.5% increase from $1.2 million in Q1 2024, with gross margins improving to 68.5% from 56.4%[1] - The company reported a net loss of $1.85 million in Q1 2025, an improvement from a net loss of $4.63 million in Q1 2024[10] Operating Expenses and Cash Flow - Total operating expenses decreased to $4.8 million in Q1 2025, a 19% reduction from $5.9 million in Q1 2024, primarily due to a $0.8 million decrease in selling expenses[1] - Cash used in operations was $3.1 million in Q1 2025, a 30% reduction from $4.4 million in Q1 2024, reflecting improved cost control[1] Balance Sheet and Liquidity - Current liabilities decreased by $1.7 million, or 30.1%, to $3.8 million as of March 31, 2025, from $5.5 million as of December 31, 2024[1] - Cash on hand increased to $3.3 million as of March 31, 2025, compared to $1.8 million as of December 31, 2024[1] Sales and Leadership - The new leadership team has focused on improving sales productivity, achieving a 94% increase in revenue per full-time equivalent salesperson compared to Q1 2024[1] Research and Development - The company is committed to an aggressive R&D timeline for ENDOInform™, with material updates expected by the end of 2025[2] - Aspira is developing a non-invasive test for endometriosis, aiming to enhance the sensitivity and specificity of current tests by combining microRNA and protein biomarkers with patient data[5]

Core Insights - Ascend Wellness Holdings, Inc. reported Q1 2025 net revenue of $128.0 million, a decrease of 5.9% quarter-over-quarter, with retail revenue down 6.6% and wholesale revenue down 4.4% [1][7][8] - The company generated positive cash from operations of $5.9 million, marking the ninth consecutive quarter of positive operating cash flow [1][11] - The company ended Q1 2025 with $100.0 million in cash and cash equivalents, reflecting a sequential increase of $11.7 million [1][11] Business Highlights - The company is focused on executing a densification strategy aimed at increasing store count by approximately 50% in the medium term, targeting ten new stores in 2025 [6][7] - New product launches and store openings are anticipated in the coming months to enhance consumer experience and expand access [6][7] Financial Highlights - Adjusted EBITDA for Q1 2025 was $27.0 million, representing a margin of 21.1%, a decrease of 10.7% from the previous quarter [7][11] - The net loss for Q1 2025 was $19.3 million, compared to a net loss of $16.8 million in Q4 2024 [7][10] - Total general and administrative expenses decreased to $37.1 million, or 29.0% of revenue, down from $40.8 million, or 30.0% of revenue, in Q4 2024 [10][11] Revenue Breakdown - Total net revenue of $128.0 million included retail revenue of $84.4 million and wholesale revenue of $43.6 million, both showing declines due to competitive pressures and pricing [7][8] - Gross profit for Q1 2025 was $39.6 million, or 30.9% of revenue, down from $46.9 million, or 34.5% of revenue, in Q4 2024 [9][11] Cash Flow and Balance Sheet - Free Cash Flow for Q1 2025 was $1.2 million, calculated as cash from operations minus capital expenditures [5][11] - Net Debt as of March 31, 2025, was $233.0 million, reflecting total debt less cash and cash equivalents [4][11] - The company launched a share buyback program in January 2025, repurchasing 1,571,500 shares by April 30, 2025 [7]

Core Points - Ascend Wellness Holdings, Inc. will hold a conference call on May 12, 2025, at 5:00 PM ET to discuss its first quarter 2025 financial results [1] - The conference call can be accessed via a dial-in number or a live webcast on the company's Investor Relations website [2][3] - Ascend Wellness Holdings operates in multiple states including Illinois, Maryland, Massachusetts, Michigan, New Jersey, Ohio, and Pennsylvania, and is involved in the cultivation and distribution of cannabis products [3]

Financial Performance - Total revenue for the year ended December 31, 2024, was $9,182,000, a slight increase of $28,000 or 0.3% compared to $9,154,000 in 2023[305] - The net loss for the year ended December 31, 2024, was $13,094,000, a decrease of $3,596,000 or 22% compared to a net loss of $16,690,000 in 2023[305] - Other income increased by $1,386,000 in 2024, primarily due to a one-time federal government award of $2,000,000[315] - The accumulated deficit as of December 31, 2024, was approximately $531,397,000, with expectations of incurring a net loss in 2025[303] Expenses - Cost of product revenue decreased by $189,000 or 5% to $3,703,000 in 2024, primarily due to reduced consulting costs and lab supplies[307] - Research and development expenses decreased by $769,000 or 19% to $3,266,000 in 2024, mainly due to lower employment-related expenses and clinical trial costs[308] - Sales and marketing expenses increased by $334,000 or 4% to $8,146,000 in 2024, driven by costs related to the contracted sales team and increased personnel costs[310] - General and administrative expenses decreased by $1,922,000 or 16% to $10,345,000 in 2024, attributed to reductions in employment-related expenses and consulting costs[311] Cash Flow - Net cash used in operating activities was $12,113,000 for the year ended December 31, 2024, primarily due to a net loss of $13,094,000 and changes in fair value of warrant liabilities totaling approximately $1,346,000[318] - Net cash used in operating activities was $15,894,000 for the year ended December 31, 2023, resulting from a net loss of $16,690,000 and the forgiveness of a DECD loan of $1,000,000[319] - Net cash provided by financing activities was $11,064,000 for the year ended December 31, 2024, mainly from a registered direct offering with net proceeds of $4,830,000[321] - Net cash provided by financing activities was $5,216,000 for the year ended December 31, 2023, primarily from a registered direct offering with net proceeds of $4,119,000[322] Future Outlook - The company plans to continue expanding access to its tests among Medicaid patients and advocate for legislation to enhance product adoption[295] - The company expects to raise additional capital through public or private equity offerings, debt financing, collaborations, or licensing arrangements to continue operations through 2025 and beyond[328] - The company expects to incur a net loss and negative cash flows from operations in 2025[369] - The company expects revenue from its products to be its only material, recurring source of cash in 2025[368] Share Issuance - For the year ended December 31, 2023, the company sold 472,312 shares for gross proceeds of approximately $1,578,000 under the 2023 Equity Line of Credit Agreement[345] - In 2024, the company sold 949,574 shares under the same agreement for gross proceeds of approximately $1,900,000, totaling 1,310,517 shares and approximately $3,078,000 over the agreement's life[346] - The company issued 1,650,473 shares at an offering price of $2.75 per share, generating gross proceeds of approximately $4.7 million from the 2023 Direct Offering[349] - The 2024 Direct Offering generated gross proceeds of approximately $5,563,000 from the issuance of 1,368,600 shares at an offering price of $3.50 per share[352] - The company sold 1,073,050 shares under the 2024 At the Market Offering for gross proceeds of approximately $903,000 during the year ended December 31, 2024[360] - The company raised approximately $1,909,000 from the 2024 Private Placement Offering by issuing 1,248,529 shares and accompanying warrants[357] Licensing and Collaborations - The company entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, with an initial license fee of $75,000 and potential royalty payments of up to $1,350,000 based on regulatory approvals and commercialization milestones[336] - Royalty expenses for the years ended December 31, 2024, and 2023 totaled $293,000 and $324,000, respectively, related to a research collaboration agreement[333] Financial Position - The company has significant NOL carryforwards as of December 31, 2024, which are subject to a full valuation allowance due to a history of operating losses[323] - The company incurred an accumulated deficit of $531,397,000 and a stockholders' deficit of $2,563,000 as of December 31, 2024[368] - The company has $1,769,000 in cash and cash equivalents and $5,468,000 in current liabilities as of December 31, 2024[368]

Revenue Performance - Record OvaSuite revenue of $9.2 million and volume of 24,305 units sold for the year ended December 31, 2024[1] - Product revenue increased 9.5% to $2.3 million for Q4 2024 compared to $2.1 million for Q4 2023[4] - The number of OvaSuite tests performed increased 6.1% to approximately 6,004 in Q4 2024 compared to approximately 5,659 in Q4 2023[4] Profitability - Gross profit margin improved 6.2 percentage points to 63.4% for Q4 2024 compared to 57.2% for Q4 2023[4] Operating Expenses - Total operating expenses decreased by $0.4 million, or 8%, to $4.9 million for Q4 2024 compared to the same period in 2023[4] - Total operating expenses for the year ended December 31, 2024, were $21.8 million, a decrease of $2.4 million, or 10%, compared to 2023[4] Cash Position - Cash balance as of March 27, 2024, was approximately $3.7 million, excluding a pending $1.5 million ARPA-H milestone payment[4] Strategic Initiatives - The company aims to accelerate top-line revenue growth through an improved go-to-market strategy in 2025[5] - The company received a $10 million Federal Government investment in ENDOinform, which will support its research and development pipeline[5] Pricing - Average unit price (AUP) decreased 1.0% to $378 for the year ended December 31, 2024, compared to $382 for the same period in 2023[4]